Commercial Progress in USA

AI SummaryClose X

Cizzle Biotechnology Holdings plc announced that its North American licensing partner, Cizzle Bio Inc (BIO), has agreed with a multi-site clinical diagnostics laboratory group to launch the company's CIZ1B biomarker test in the USA. This follows progress with a pathfinder laboratory. BIO has made an early payment of US$125,000 in advance royalties, bringing total receipts to US$525,000 against guaranteed advance payments of US$2.4 million. A revised payment schedule means the remaining US$1,875,000 will be received by the end of 2026, earlier than the previously agreed April 2027 deadline.

Disclaimer*

UK 100

Latest directors dealings